One of the most important tools, and perhaps one of the most confusing tools, for metallurgists is the binary phase diagram.

Incendia Therapeutics has enrolled the first subject in a Phase Ic clinical trial of PRTH-101, a novel DDR1 inhibitor aimed ...

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase ...

The use of targeted therapy significantly improved ORR and PFS in patients with a long-term PFS benefit at one year and ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Broadcom has an excellent growth runway, substantial sales and profitability growth potential, and is relatively cheap now.

Additional Phase 2 studies in solid tumors are planned to begin in 2025.” CBX-12 is designed to deliver higher concentrations of exatecan, a topoisomerase 1 (TOP1) inhibitor, directly to tumor ...

Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the ...

TRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1/2 dose-escalation and expansion study ... activity associated with camonsertib monotherapy in patients with solid tumors ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ...